BG98628A - The use of peptidoglycan monomer (pgm) and its n-acyl derivatives and metal complexes for the production of medicines for the correction of immunosuppressive and hepatosuppressive conditions of the organism - Google Patents

The use of peptidoglycan monomer (pgm) and its n-acyl derivatives and metal complexes for the production of medicines for the correction of immunosuppressive and hepatosuppressive conditions of the organism

Info

Publication number
BG98628A
BG98628A BG98628A BG9862894A BG98628A BG 98628 A BG98628 A BG 98628A BG 98628 A BG98628 A BG 98628A BG 9862894 A BG9862894 A BG 9862894A BG 98628 A BG98628 A BG 98628A
Authority
BG
Bulgaria
Prior art keywords
hepatosuppressive
immunosuppressive
pgm
conditions
metal complexes
Prior art date
Application number
BG98628A
Other languages
Bulgarian (bg)
Inventor
Biserka Radosevi-Stasic
Bozidar Suskovic
Radmila Naumski
Danijel Rukavina
Original Assignee
Pliva Farmaceutska,Kemijska,Prehrambena Ikozmeticka Industrija Dionicko Drustvo
Pliva Handels Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Farmaceutska,Kemijska,Prehrambena Ikozmeticka Industrija Dionicko Drustvo, Pliva Handels Gmbh filed Critical Pliva Farmaceutska,Kemijska,Prehrambena Ikozmeticka Industrija Dionicko Drustvo
Publication of BG98628A publication Critical patent/BG98628A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретението се отнася до използването на пгм, неговите n-ацилни производни с формула, дадена в описанието, и металните му комплекси с формули iа и iв, дадени в описанието, при изготвяне на лекарствени средства за коригиране на имуносупресивното и хепатосупресивното влияние на анестетиците и на операционния стрес при хирургическо лечение и при други имуносупресивни, имунодефицитни и хепатосупресивни състояния. С пгм се осигурява бързо и безопасно възстановяване на болните.The invention relates to the use of pg, its n-acyl derivatives of the formula given in the description and its metal complexes of the formulas ia and ib given in the description in the preparation of medicaments for correcting the immunosuppressive and hepatosuppressive effects of the anesthetics and of the surgical stress in surgical treatment, and other immunosuppressive, immunodeficiency and hepatosuppressive conditions. Pgm provides fast and safe recovery of the patients.

BG98628A 1991-08-15 1994-03-01 The use of peptidoglycan monomer (pgm) and its n-acyl derivatives and metal complexes for the production of medicines for the correction of immunosuppressive and hepatosuppressive conditions of the organism BG98628A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
YU141291 1991-08-15
PCT/EP1992/001859 WO1993003746A1 (en) 1991-08-15 1992-08-13 Preparation of medicaments containing the peptidoglycan monomer or its derivatives

Publications (1)

Publication Number Publication Date
BG98628A true BG98628A (en) 1995-06-30

Family

ID=25554075

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98628A BG98628A (en) 1991-08-15 1994-03-01 The use of peptidoglycan monomer (pgm) and its n-acyl derivatives and metal complexes for the production of medicines for the correction of immunosuppressive and hepatosuppressive conditions of the organism

Country Status (10)

Country Link
EP (1) EP0600974A1 (en)
JP (1) JPH08506796A (en)
BG (1) BG98628A (en)
CA (1) CA2115270A1 (en)
CZ (1) CZ30194A3 (en)
HR (1) HRP920488A2 (en)
HU (1) HU9400420D0 (en)
RU (1) RU94027699A (en)
SK (1) SK17994A3 (en)
WO (1) WO1993003746A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8611982A8 (en) * 1986-11-19 1995-04-30 Pliva Pharm & Chem Works Process for preparing complexes of N-acethyl-glucosisaminyl-N-acethyl- muramoil-L-alanyl-D-izoglutaminyl-(L)-mezodiaminopimelyl-(D-amid)- (L)-alanyl-D-alanine
US4868155A (en) * 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
YU62689A (en) * 1989-03-27 1991-02-28 Pliva Pharm & Chem Works N-acyl derivatives of peptidoglican monomer, their pharmaceutically acceptable salts, process for preparing thereof and their use as immunity modulators and immunoadjuvant

Also Published As

Publication number Publication date
HRP920488A2 (en) 1994-08-31
RU94027699A (en) 1996-04-10
CA2115270A1 (en) 1993-03-04
WO1993003746A1 (en) 1993-03-04
JPH08506796A (en) 1996-07-23
EP0600974A1 (en) 1994-06-15
HU9400420D0 (en) 1994-08-29
SK17994A3 (en) 1994-08-10
CZ30194A3 (en) 1994-06-15

Similar Documents

Publication Publication Date Title
DK602988A (en) NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL EFFECT AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS
NO302574B1 (en) Indolcarbazolimides and their use
HUP0204023A2 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders and pharmaceutical compositions containing them
PT87542A (en) PROCESS FOR THE PREPARATION OF A MEDICINAL BASED ON INDOLONE DERIVATIVES FOR THE TREATMENT OF THE PARKINSON DISEASE
IL127352A (en) Pyridyl alkene- and pyridyl alkine-acid amides and pharmaceutical compositions containing them
NO174202C (en) Analogous process for the preparation of therapeutically active azainden derivatives
KR930702022A (en) Treatment or prevention of type 1 diabetes by oral administration of insulin
MY102016A (en) Thiazolidinedione derivatives, their production and use.
DK0660705T3 (en) Advanced drug delivery system and method for treating psychiatric, neurological and other disorders with approx.
KR950703951A (en) ANTIPYRETIC AND ANALGESIC METHODS AND COMPOSITIONS CONTAINING OPTICALLY PURE R-KETOROLAC
HUP9900186A2 (en) Use of lamellarin alkaloids in therapy and pharmaceutical compositions containing them
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
NO20053032L (en) Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on a disturbance of NO production and / or regulation of EDHF function.
BG98628A (en) The use of peptidoglycan monomer (pgm) and its n-acyl derivatives and metal complexes for the production of medicines for the correction of immunosuppressive and hepatosuppressive conditions of the organism
IL126795A (en) Pharmaceutical compositions for the treatment of substance abuse disorders comprising pyridyl- and pyrimidyl-piperazines
DE60027691D1 (en) BETA-D-2 ', 3'-DIDEHYDRO-2', 3'-DIDESOXY-5-FLUOROCYTIDINE FOR THE USE IN THE TREATMENT OF HIV INFECTIONS
UA42693C2 (en) The medicine for treating the infection by lentivirus, the preparation for human treatment which is infected by lentivirus.
KR890001555A (en) Uric acid excretion composition
HUP9801545A2 (en) 2-methyl-4-izothiazolin-3-one derivatives, cystinediamides and process for producing them, and use of the compounds
RU93037848A (en) METHOD OF TREATMENT OF LEPROI PATIENTS
UA19421C2 (en) The method for treatment of patients with intoxication
UA6981A (en) METHOD OF HEMOSORPTION
CY1115006T1 (en) LONG-TERM RELEASE OF ANTI-COLLAPSE MEDICINES
RU2001102089A (en) METHOD FOR TREATMENT OF DISCIRCULATORY ENCEPHALOPATHY
RU2001123676A (en) Medication for the treatment of intermittent claudication